NASDAQ:NTRA - Natera Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $87.50
  • Forecasted Upside: 58.60 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$55.17
▲ +1.58 (2.95%)

This chart shows the closing price for NTRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Natera Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTRA

Analyst Price Target is $87.50
▲ +58.60% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Natera in the last 3 months. The average price target is $87.50, with a high forecast of $110.00 and a low forecast of $54.00. The average price target represents a 58.60% upside from the last price of $55.17.

This chart shows the closing price for NTRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Natera. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/18/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022JPMorgan Chase & Co.Boost Price Target$80.00 ➝ $100.00Low
5/15/2022Piper SandlerLower Price TargetNA$75.00 ➝ $60.00Low
5/6/2022CowenLower Price Target$110.00 ➝ $100.00High
5/6/2022CowenLower Price Target$110.00 ➝ $100.00High
5/6/2022Robert W. BairdLower Price Target$100.00 ➝ $71.00High
4/25/2022StephensInitiated CoverageOverweight$54.00High
4/19/2022The Goldman Sachs GroupLower Price TargetBuy$90.00 ➝ $80.00High
4/13/2022Piper SandlerBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $75.00Medium
3/21/2022Piper SandlerLower Price TargetOverweight$80.00 ➝ $70.00Medium
3/10/2022BTIG ResearchLower Price Target$125.00 ➝ $100.00High
3/8/2022The Goldman Sachs GroupInitiated CoverageBuy$90.00High
3/1/2022Piper SandlerLower Price Target$110.00 ➝ $80.00Medium
2/28/2022Morgan StanleyLower Price TargetOverweight$118.00 ➝ $110.00Medium
2/25/2022Robert W. BairdLower Price TargetOutperform$152.00 ➝ $100.00High
2/17/2022CowenLower Price Target$150.00 ➝ $110.00High
2/15/2022Morgan StanleyLower Price TargetOverweight$148.00 ➝ $118.00Medium
1/24/2022Wells Fargo & CompanyLower Price Target$135.00 ➝ $100.00High
1/12/2022BTIG ResearchLower Price Target$150.00High
1/6/2022Piper SandlerInitiated CoverageOverweight$110.00Low
11/5/2021Robert W. BairdBoost Price TargetOutperform$145.00 ➝ $152.00High
10/15/2021CowenInitiated CoverageOutperform$150.00Low
8/9/2021Piper SandlerBoost Price TargetOverweight$155.00 ➝ $160.00Medium
8/6/2021Wells Fargo & CompanyBoost Price TargetOverweight$125.00 ➝ $135.00High
8/6/2021Robert W. BairdBoost Price TargetOutperform$127.00 ➝ $145.00High
8/6/2021BTIG ResearchBoost Price TargetBuy$155.00 ➝ $160.00High
7/20/2021Craig HallumBoost Price TargetBuy$134.00 ➝ $139.00Low
7/6/2021Piper SandlerBoost Price TargetOverweight$150.00 ➝ $155.00Low
6/23/2021BTIG ResearchBoost Price TargetBuy$150.00 ➝ $155.00Medium
6/21/2021Wells Fargo & CompanyBoost Price TargetOverweight$110.00 ➝ $125.00High
6/21/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$140.00 ➝ $160.00High
6/15/2021Raymond JamesInitiated CoverageMarket PerformMedium
5/25/2021Truist FinancialLower Price TargetBuy$143.00 ➝ $129.00High
5/25/2021Wells Fargo & CompanyInitiated CoverageOverweight$110.00High
5/10/2021Morgan StanleyLower Price TargetOverweight$140.00 ➝ $135.00High
5/7/2021BTIG ResearchBoost Price TargetBuy$145.00 ➝ $150.00Medium
3/1/2021Morgan StanleyBoost Price TargetOverweight$87.00 ➝ $140.00Low
2/26/2021Piper SandlerBoost Price TargetTop Pick ➝ Overweight$127.00 ➝ $150.00Medium
1/27/2021Truist FinancialInitiated CoverageBuy$143.00High
1/20/2021SVB LeerinkBoost Price TargetOutperform$95.00 ➝ $140.00Low
1/19/2021BTIG ResearchBoost Price TargetBuy$112.00 ➝ $135.00Medium
1/4/2021Craig HallumBoost Price TargetBuy$92.00 ➝ $118.00N/A
12/16/2020Piper SandlerBoost Price TargetPositive ➝ Overweight$92.00 ➝ $127.00High
12/2/2020BTIG ResearchBoost Price TargetAverage ➝ Buy$95.00 ➝ $105.00Medium
11/13/2020SVB LeerinkBoost Price TargetOutperform$84.00 ➝ $95.00Low
11/6/2020JPMorgan Chase & Co.Boost Price TargetOverweight$75.00 ➝ $90.00High
11/6/2020Morgan StanleyBoost Price TargetAverage ➝ Overweight$80.00 ➝ $87.00High
11/6/2020Piper SandlerBoost Price TargetOverweight$76.00 ➝ $92.00High
11/6/2020SVB LeerinkBoost Price TargetOutperform$75.00 ➝ $84.00High
10/7/2020BTIG ResearchInitiated CoverageBuy$90.00Medium
9/28/2020Morgan StanleyInitiated CoverageOverweight$80.00Medium
9/24/2020Craig HallumBoost Price TargetBuy$66.00 ➝ $82.00High
9/17/2020SVB LeerinkInitiated CoverageOutperform$75.00Low
8/6/2020Robert W. BairdBoost Price TargetOutperform$42.00 ➝ $60.00High
8/6/2020JPMorgan Chase & Co.Boost Price TargetOverweight$45.00 ➝ $60.00High
6/22/2020Piper SandlerReiterated RatingBuy$63.00Low
5/21/2020CfraLower Price TargetBuy ➝ Hold$39.00 ➝ $36.00Low
5/14/2020Piper SandlerBoost Price TargetOverweight$49.00 ➝ $56.00Medium
5/7/2020Robert W. BairdBoost Price TargetOutperform$40.00 ➝ $42.00High
5/7/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$32.00 ➝ $45.00High
4/15/2020CowenBoost Price TargetOutperform$32.00 ➝ $40.00Medium
2/27/2020Piper SandlerBoost Price TargetOverweight$45.00 ➝ $49.00High
12/19/2019Craig HallumReiterated RatingBuy$49.00High
11/7/2019Craig HallumBoost Price TargetBuy$37.00 ➝ $49.00High
11/4/2019JPMorgan Chase & Co.Boost Price TargetNeutral$27.00 ➝ $32.00High
10/18/2019CowenBoost Price TargetOutperform ➝ Average$30.00 ➝ $42.00Low
10/11/2019Piper Jaffray CompaniesSet Price TargetBuy$45.00Low
9/24/2019Piper Jaffray CompaniesBoost Price TargetOverweight$32.00 ➝ $45.00Low
8/22/2019Piper Jaffray CompaniesReiterated RatingBuyLow
8/8/2019Craig HallumBoost Price TargetBuy$29.00 ➝ $37.00High
8/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight$28.00 ➝ $32.00High
6/10/2019Piper Jaffray CompaniesBoost Price TargetAverage ➝ Overweight$23.00 ➝ $28.00High
11/9/2018CowenReiterated RatingBuy$30.00High
10/5/2018JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$26.00High
9/28/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $41.00High
8/9/2018Craig HallumBoost Price TargetBuy$23.00 ➝ $30.00High
8/9/2018Piper Jaffray CompaniesBoost Price TargetOverweight$27.00High
7/5/2018Piper Jaffray CompaniesReiterated RatingOverweight$18.00 ➝ $21.00High
6/28/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $20.00Low
6/28/2018Craig HallumSet Price TargetBuy ➝ Positive$16.00 ➝ $23.00High
6/25/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $20.00High
5/9/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$15.00 ➝ $16.00Low
4/9/2018Craig HallumInitiated CoverageBuy$16.00High
12/21/2017CowenReiterated RatingBuy$12.00Low
10/24/2017Robert W. BairdReiterated RatingBuyN/A
10/6/2017Morgan StanleyReiterated RatingOverweight$13.00 ➝ $16.00N/A
9/1/2017CowenReiterated RatingBuy$14.00Low
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
1/14/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/13/2022
  • 5 very positive mentions
  • 29 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
3/15/2022
  • 4 very positive mentions
  • 18 positive mentions
  • 9 negative mentions
  • 3 very negative mentions
4/14/2022
  • 5 very positive mentions
  • 32 positive mentions
  • 11 negative mentions
  • 8 very negative mentions
5/14/2022
  • 5 very positive mentions
  • 21 positive mentions
  • 7 negative mentions
  • 4 very negative mentions
6/13/2022
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/13/2022
  • 4 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
8/12/2022

Current Sentiment

  • 4 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Natera logo
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Read More

Today's Range

Now: $55.17
Low: $53.49
High: $56.44

50 Day Range

MA: $41.43
Low: $31.69
High: $55.29

52 Week Range

Now: $55.17
Low: $26.10
High: $129.09

Volume

1,287,542 shs

Average Volume

1,907,211 shs

Market Capitalization

$5.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Natera?

The following Wall Street research analysts have issued stock ratings on Natera in the last year: BTIG Research, Cowen Inc, Cowen Inc., JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Robert W. Baird, Stephens, StockNews.com, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for NTRA.

What is the current price target for Natera?

10 Wall Street analysts have set twelve-month price targets for Natera in the last year. Their average twelve-month price target is $87.50, suggesting a possible upside of 58.6%. Morgan Stanley has the highest price target set, predicting NTRA will reach $110.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $54.00 for Natera in the next year.
View the latest price targets for NTRA.

What is the current consensus analyst rating for Natera?

Natera currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NTRA will outperform the market and that investors should add to their positions of Natera.
View the latest ratings for NTRA.

What other companies compete with Natera?

How do I contact Natera's investor relations team?

Natera's physical mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company's listed phone number is (650) 249-9090 and its investor relations email address is [email protected] The official website for Natera is www.natera.com. Learn More about contacing Natera investor relations.